DK1028729T3 - Fremgangsmåder til modulering af serin/threoninproteinkinasefunktion med 5-azaquinoxalinbaserede forbindelser - Google Patents

Fremgangsmåder til modulering af serin/threoninproteinkinasefunktion med 5-azaquinoxalinbaserede forbindelser

Info

Publication number
DK1028729T3
DK1028729T3 DK98948606T DK98948606T DK1028729T3 DK 1028729 T3 DK1028729 T3 DK 1028729T3 DK 98948606 T DK98948606 T DK 98948606T DK 98948606 T DK98948606 T DK 98948606T DK 1028729 T3 DK1028729 T3 DK 1028729T3
Authority
DK
Denmark
Prior art keywords
azaquinoxaline
methods
protein kinase
based compounds
threonine protein
Prior art date
Application number
DK98948606T
Other languages
Danish (da)
English (en)
Inventor
Gerald Mcmahon
Bernhard Kutscher
Eckhard Guenther
Harald App
Original Assignee
Zentaris Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zentaris Gmbh filed Critical Zentaris Gmbh
Application granted granted Critical
Publication of DK1028729T3 publication Critical patent/DK1028729T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK98948606T 1997-10-06 1998-10-05 Fremgangsmåder til modulering af serin/threoninproteinkinasefunktion med 5-azaquinoxalinbaserede forbindelser DK1028729T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6112397P 1997-10-06 1997-10-06

Publications (1)

Publication Number Publication Date
DK1028729T3 true DK1028729T3 (da) 2006-12-11

Family

ID=22033733

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98948606T DK1028729T3 (da) 1997-10-06 1998-10-05 Fremgangsmåder til modulering af serin/threoninproteinkinasefunktion med 5-azaquinoxalinbaserede forbindelser

Country Status (31)

Country Link
US (2) US6180631B1 (fr)
EP (1) EP1028729B1 (fr)
JP (1) JP2001518496A (fr)
KR (1) KR100633270B1 (fr)
CN (1) CN1169527C (fr)
AR (1) AR013542A1 (fr)
AT (1) ATE336250T1 (fr)
AU (1) AU757585B2 (fr)
BG (1) BG64969B1 (fr)
BR (1) BR9814814A (fr)
CA (1) CA2306257C (fr)
CY (1) CY1106223T1 (fr)
CZ (1) CZ298775B6 (fr)
DE (1) DE69835612T2 (fr)
DK (1) DK1028729T3 (fr)
ES (1) ES2268791T3 (fr)
HK (1) HK1031836A1 (fr)
HU (1) HUP0100302A3 (fr)
IL (2) IL135103A0 (fr)
MX (1) MXPA03011007A (fr)
NO (1) NO316598B1 (fr)
NZ (1) NZ503431A (fr)
PL (1) PL192039B1 (fr)
PT (1) PT1028729E (fr)
RU (1) RU2223753C2 (fr)
SK (1) SK4722000A3 (fr)
TR (2) TR200000906T2 (fr)
TW (1) TWI245765B (fr)
UA (1) UA71555C2 (fr)
WO (1) WO1999017759A2 (fr)
ZA (1) ZA988961B (fr)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA71555C2 (en) 1997-10-06 2004-12-15 Zentaris Gmbh Methods for modulating function of serine/threonine protein kinases by 5-azaquinoline derivatives
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
CA2359244C (fr) * 1999-01-13 2013-10-08 Bayer Corporation Diphenyle urees a substitution .omega.-carboxy aryle en tant qu'inhibiteurs de la kinase p38
AU1053501A (en) * 1999-11-02 2001-05-14 Ajinomoto Co., Inc. Polyazanaphthalene compound and medicinal use thereof
US7371763B2 (en) * 2001-04-20 2008-05-13 Bayer Pharmaceuticals Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
US20080108672A1 (en) * 2002-01-11 2008-05-08 Bernd Riedl Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors
DK1478358T3 (da) 2002-02-11 2013-10-07 Bayer Healthcare Llc Sorafenibtosylat til behandling af sygdomme kendetegnet ved unormal angiogenese
US20040131504A1 (en) * 2002-09-17 2004-07-08 Landers James P. Remote temperature sensing of small volume and related apparatus thereof
UY28213A1 (es) 2003-02-28 2004-09-30 Bayer Pharmaceuticals Corp Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos.
PT1626714E (pt) * 2003-05-20 2007-08-24 Bayer Pharmaceuticals Corp Diarilureias para doenças mediadas por pdgfr
DE102004022383A1 (de) * 2004-05-06 2005-12-01 Zentaris Gmbh Neue Pyridopyrazine und deren Verwendung als Modulatoren von Kinasen
PT1636228E (pt) 2003-05-23 2009-02-02 Aeterna Zentaris Gmbh Novas piridopirazinas e sua utilização como moduladores de cinases
DE10323345A1 (de) 2003-05-23 2004-12-16 Zentaris Gmbh Neue Pyridopyrazine und deren Verwendung als Kinase-Inhibitoren
MXPA05013349A (es) * 2003-06-13 2006-03-09 Novartis Ag Derivados de 2-amino-pirimidina como inhibidores de quinasa raf.
ES2297490T3 (es) 2003-07-23 2008-05-01 Bayer Pharmaceuticals Corporation Omega-carboxiarildifenilurea fluoro sustituida para el tratamiento y prevencion de enfermadades y afecciones.
EP1790342A1 (fr) 2005-11-11 2007-05-30 Zentaris GmbH Dérivés de pyridopyrazine et leur utilisation comme modulateurs de transduction de signal
KR101400905B1 (ko) 2005-11-11 2014-05-29 아에테르나 젠타리스 게엠베하 신규한 피리도피라진 및 키나제의 조절제로서의 이의 용도
US8217042B2 (en) 2005-11-11 2012-07-10 Zentaris Gmbh Pyridopyrazines and their use as modulators of kinases
WO2010003308A1 (fr) * 2008-07-10 2010-01-14 卞化石 Utilisation de l’oxyde nitrique et de son système de transduction des signaux dans la préparation de médicaments destinés à une thérapie ciblée de tumeurs malignes
GB0812969D0 (en) 2008-07-15 2008-08-20 Sentinel Oncology Ltd Pharmaceutical compounds
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
GB201020179D0 (en) 2010-11-29 2011-01-12 Astex Therapeutics Ltd New compounds
EP2508184A1 (fr) 2011-04-06 2012-10-10 Æterna Zentaris GmbH Dérivés de pyridopyrazine et leur utilisation
GB201118652D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118654D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118675D0 (en) 2011-10-28 2011-12-14 Astex Therapeutics Ltd New compounds
GB201118656D0 (en) * 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201209613D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
GB201209609D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
BR112015016580A2 (pt) 2013-01-11 2017-07-11 Fujifilm Corp composto heterocíclico contendo nitrogênio ou sal deste
GB201307577D0 (en) 2013-04-26 2013-06-12 Astex Therapeutics Ltd New compounds
DE102013008118A1 (de) * 2013-05-11 2014-11-13 Merck Patent Gmbh Arylchinazoline
JO3512B1 (ar) 2014-03-26 2020-07-05 Astex Therapeutics Ltd مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
PL3122358T3 (pl) 2014-03-26 2021-06-14 Astex Therapeutics Ltd. Połączenia inhibitorów fgfr i cmet w leczeniu nowotworu
RU2715893C2 (ru) 2014-03-26 2020-03-04 Астекс Терапьютикс Лтд Комбинации ингибитора fgfr и ингибитора igf1r
ES2896400T3 (es) 2014-08-01 2022-02-24 Nuevolution As Compuestos activos frente a bromdominios
JOP20200201A1 (ar) 2015-02-10 2017-06-16 Astex Therapeutics Ltd تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
BR112018005637B1 (pt) 2015-09-23 2023-11-28 Janssen Pharmaceutica Nv Compostos derivados de quinoxalina, quinolina e quinazolinona,composições farmacêuticas que os compreende, e uso dos referidos compostos
HUE057090T2 (hu) 2015-09-23 2022-04-28 Janssen Pharmaceutica Nv BI-heteroaril-szubsztituált 1,4-benzodiazepinek és alkalmazásuk rák kezelésében
US12012394B2 (en) * 2018-02-19 2024-06-18 Washington University Alpha-synuclein ligands

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4001017A (en) * 1972-12-05 1977-01-04 Ciba-Geigy Ag Process for the photopolymerization of ethylenically unsaturated compounds
US4043819A (en) * 1974-06-11 1977-08-23 Ciba-Geigy Ag Photo-polymerizable material for the preparation of stable polymeric images and process for making them by photopolymerization in a matrix
US5217999A (en) 1987-12-24 1993-06-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Styryl compounds which inhibit EGF receptor protein tyrosine kinase
DE3804990A1 (de) * 1988-02-18 1989-08-31 Basf Ag Herbizid wirksame, heterocyclisch substituierte sulfonamide
FR2656606B1 (fr) * 1989-12-28 1993-06-25 Roussel Uclaf Utilisation de derives du 9,10-dihydrophenanthrene pour la preparation d'un medicament anti-tumoral, application a titre de medicaments de derives du 9,10-dihydrophenanthrene et produits derives de cette structure.
ES2064101T3 (es) 1990-04-02 1995-01-16 Pfizer Compuestos de acido bencilfosfonico inhibidores de la quinasa de tirosina.
US5302606A (en) 1990-04-16 1994-04-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Styryl-substituted pyridyl compounds which inhibit EGF receptor tyrosine kinase
WO1992020642A1 (fr) 1991-05-10 1992-11-26 Rhone-Poulenc Rorer International (Holdings) Inc. Composes aryle et heteroaryle bis monocycliques et/ou bicycliques qui inhibent la tyrosine kinase d'un recepteur du egf et/ou du pdgf
JPH06503095A (ja) 1991-05-29 1994-04-07 ファイザー・インコーポレーテッド 三環式ポリヒドロキシ系のチロシンキナーゼ阻害薬
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
AU672224B2 (en) 1992-08-06 1996-09-26 Warner-Lambert Company 2-thioindoles (selenoindoles) and related disulfides (selenides) which inhibit protein tyrosine kinases and whichhave antitumor properties
US5330992A (en) 1992-10-23 1994-07-19 Sterling Winthrop Inc. 1-cyclopropyl-4-pyridyl-quinolinones
GB9226855D0 (en) 1992-12-23 1993-02-17 Erba Carlo Spa Vinylene-azaindole derivatives and process for their preparation
US5700823A (en) * 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
GB9501567D0 (en) 1995-01-26 1995-03-15 Pharmacia Spa Hydrosoluble 3-arylidene-2-oxindole derivatives as tyrosine kinase inhibitors
US5593997A (en) * 1995-05-23 1997-01-14 Pfizer Inc. 4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
US5723462A (en) * 1996-04-26 1998-03-03 Neurogen Corporation Certain fused pyrrolecarboxamides a new class of GABA brain receptor ligands
UA71555C2 (en) 1997-10-06 2004-12-15 Zentaris Gmbh Methods for modulating function of serine/threonine protein kinases by 5-azaquinoline derivatives
GB9726851D0 (en) * 1997-12-19 1998-02-18 Zeneca Ltd Human signal transduction serine/threonine kinase

Also Published As

Publication number Publication date
CZ298775B6 (cs) 2008-01-23
EP1028729B1 (fr) 2006-08-16
HUP0100302A3 (en) 2006-03-28
AU9514198A (en) 1999-04-27
US6180631B1 (en) 2001-01-30
PL192039B1 (pl) 2006-08-31
BR9814814A (pt) 2000-10-03
NZ503431A (en) 2002-07-26
KR100633270B1 (ko) 2006-10-16
WO1999017759A3 (fr) 2000-01-06
CZ20001129A3 (cs) 2000-10-11
WO1999017759A2 (fr) 1999-04-15
NO20001748L (no) 2000-04-05
NO20001748D0 (no) 2000-04-05
AR013542A1 (es) 2000-12-27
BG104392A (en) 2000-12-29
AU757585B2 (en) 2003-02-27
EP1028729A2 (fr) 2000-08-23
TWI245765B (en) 2005-12-21
BG64969B1 (bg) 2006-11-30
TR200000906T2 (tr) 2000-11-21
PL339860A1 (en) 2001-01-15
ZA988961B (en) 1999-10-04
US6727252B1 (en) 2004-04-27
CA2306257C (fr) 2007-09-25
DE69835612D1 (de) 2006-09-28
CN1169527C (zh) 2004-10-06
ES2268791T3 (es) 2007-03-16
ATE336250T1 (de) 2006-09-15
CY1106223T1 (el) 2011-06-08
JP2001518496A (ja) 2001-10-16
MXPA03011007A (es) 2004-02-27
UA71555C2 (en) 2004-12-15
NO316598B1 (no) 2004-03-01
SK4722000A3 (en) 2002-06-04
PT1028729E (pt) 2006-12-29
DE69835612T2 (de) 2007-08-16
KR20010030934A (ko) 2001-04-16
IL135103A (en) 2007-06-17
TR200100385T2 (tr) 2002-06-21
IL135103A0 (en) 2001-05-20
HUP0100302A2 (hu) 2001-06-28
RU2223753C2 (ru) 2004-02-20
CN1274284A (zh) 2000-11-22
CA2306257A1 (fr) 1999-04-15
HK1031836A1 (en) 2001-06-29

Similar Documents

Publication Publication Date Title
DK1028729T3 (da) Fremgangsmåder til modulering af serin/threoninproteinkinasefunktion med 5-azaquinoxalinbaserede forbindelser
DK1017384T3 (da) Azabenzimidazolbaserede forbindelser til modulation af serin/threoninproteinkinasefunktion
CY2008013I1 (el) Αρυλσυμπυκωμενες αζαπολυκυκλικες ενωσεις
CY2008015I1 (el) Δικυκλικες ετepοαρωματικες ενωσεις σαν αναστολεις πρωτεϊνης κινασης τυροσινης
LTPA2014028I1 (lt) Pakeistieji 3-cianochinolinai kaip proteintirozinkinazės inhibitoriai
DK0996622T3 (da) Hidtil ukendte spiroazabicycliske, heterocykliske forbindelser
DK0912559T3 (da) Kondenserede heterocykliske forbindelser som proteintyrosinkinaseinhibitorer
DK1036179T3 (da) Fremgangsmåde til fremstilling af polypeptider med egnet glucosilering
DK0812845T3 (da) Fremgangsmåde til fremstilling af sildenafil
NO990124D0 (no) Bicykliske heteroaromatiske forbindelser som protein-tyrosin-kinase-inhibitorer
NO990123D0 (no) Bicykliske heteroaromatiske forbindelser som protein-tyrosin-kinase-inhibitorer
DK0951467T3 (da) Substituerede nitrogenholdige heterocykliske forbindelser som inhibitorer af p38-proteinkinase
IS5649A (is) Arýl sambrædd azapólýsýklísk efnasambönd
DK1027315T3 (da) Fremgangsmåde til fremstilling af n-butanol
DK1028960T3 (da) Fremgangsmåde til fremstilling af thiazolidinedion
DK0970939T3 (da) Fremgangsmåde til fremstilling af methanol
DK0946514T3 (da) Fremgangsmåde til fremstilling af n-substituerede 3-hydroxypyrazoler
DE69801549D1 (de) Schwalbenschwanzförmige Flüssigkristallverbindung
DK1012152T3 (da) Fremgangsmåde til fremstilling af oxazaphosphorin-2-aminer
DK1051401T3 (da) Fremgangsmåde til fremstilling af formylimidazoler
DK0949237T3 (da) Fremgangsmåde til fremstilling af dihydrocitral
ZA983669B (en) Methods of modulating serine/threonine protein kinase function with quinazoline-based compounds.
DK0988263T3 (da) Fremgangsmåde til fremstilling af radioioderede neuroreceptormidler
DK0882035T3 (da) Fremgangsmåde til fremstilling af 2H-1-benzopyraner
DK1071674T3 (da) Fremgangsmåde til fremstilling af chlorbenzoxazoler